Browse drugs

… with CP (ICD-10-CM K86.0/K86.1) were classified by exposure to dulaglutide, semaglutide, or tirzepatide (GLP1a cohort) versus no GLP-1 ana…

…cation recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse Event Repor…

…h new generation agents and longer duration: 3 year exposure to semaglutide or tirzepatide gave an absolute risk difference of −4.71 percen…

…ular issue in Kuwait. Advances in pharmaceutical treatment (eg, glucagon-like peptide-1s) offer an effective solution, with the magnitude of weight lost…

…These findings extend safety observations beyond semaglutide to tirzepatide. Healthcare providers should consider this potential risk when …

… kidney disease progression by 24% [HR 0.76; 95% CI 0.67–0.87]. Canagliflozin reduced the composite renal outcome [HR 0.66; 95% CI 0.53–0.81]…

…78.7%), followed by semaglutide (69.6%), exenatide (49.6%), and liraglutide (39.6%).Cox regression analysis (reference: dulaglutide) showed…

… an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, pr…

…ever, these studies did not employ suitable active comparators. Metformin is often prescribed as first-line therapy in T2DM management, w…

…fects of cagrilintide/semaglutide, liraglutide, semaglutide and tirzepatide in patients with and without a history of HF. The primary outco…

…Obesity drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) produce substantial weight loss for patients but do …

…UK patients can now buy the daily pill version of semaglutide (Wegovy) for weight loss.…